Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study.
Ann Oncol
; 33(4): 416-425, 2022 04.
Article
in En
| MEDLINE
| ID: mdl-35026412
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Immunoconjugates
/
Antibodies
/
Neoplasms
/
Antineoplastic Agents
Type of study:
Guideline
/
Prognostic_studies
Limits:
Adolescent
/
Adult
/
Humans
Language:
En
Journal:
Ann Oncol
Journal subject:
NEOPLASIAS
Year:
2022
Document type:
Article